

## Lumito to present two scientific posters and exhibit at the European Congress of Pathology 2026 in Stockholm

**Lumito AB (publ) ("Lumito" or the "Company") today announces that two scientific abstracts have been accepted for poster presentation at the European Congress of Pathology 2026, taking place at Stockholmsmässan, Stockholm, Sweden, on September 12-16, 2026. The Company will also participate as an exhibitor at the congress, which is one of the largest international meetings in pathology, with a strong focus on digital pathology, artificial intelligence, and emerging technologies.**

The European Congress of Pathology is a leading international meeting in the field of pathology, with a particular emphasis on digitalisation, AI, and novel diagnostic technologies. The congress brings together researchers, clinicians, and industry representatives from around the world. Participation provides Lumito with an important platform for commercial and scientific visibility and for engagement with researchers, CROs, pharmaceutical companies, and other stakeholders in tissue analysis and diagnostics. Lumito will also exhibit at the congress to showcase its solution and meet potential collaboration partners and customers.

One of the Company's abstracts, which has been developed in collaboration with Atlas Antibodies, directly compares direct and indirect UCNP-based biomarker labeling using the SCIZYS platform. The results show that direct labeling shows a high degree of concordance with indirect labeling, while reducing the need for secondary antibodies, which may contribute to simplified workflows and improved efficiency.

The Company's second abstract, which has been developed in collaboration with Concept Life Sciences, compares Lumito's UCNP-based immunohistochemistry with a traditional staining method (HRP/DAB) in non-small cell lung cancer (NSCLC) across multiple biomarkers. The findings show higher sensitivity, wider signal range, and improved cell detection with UCNP-based labeling for the majority of the biomarkers analysed.

"ECP 2026 provides an important platform for us to present data highlighting the potential of our product offering for improved tissue analysis, both in collaboration with Atlas Antibodies and in the study conducted together with Concept Life Sciences. By also exhibiting at the congress, we are strengthening our visibility and creating valuable opportunities to engage with researchers, CROs, pharmaceutical companies, and other partners within the pathology field," says Sanna Wallenborg, CEO of Lumito.

**For further information, please contact:**

---

Sanna Wallenborg, CEO Lumito  
E-mail: [sw@lumito.se](mailto:sw@lumito.se)  
Ph: +4670-870 01 68

**About Lumito**

Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. [www.lumito.se/en/](http://www.lumito.se/en/)

The share is traded on NGM Growth Market under the name LUMITO, and Mentor is Mangold Fondkommission.

**Attachments**

[Lumito to present two scientific posters and exhibit at the European Congress of Pathology 2026 in Stockholm](#)